Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative tr

Event · Earnings
Original reporting
Published Aug 12, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 1:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MNPR
Neutral
low confidence
Mentioned
$MNPR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MNPRNeutralLow
01

Why it matters

Traders should treat this as the official release vehicle for Q2 results; however, the excerpt does not provide the figures needed to judge whether the report is a beat, miss, or includes updated outlook.

02

Market read

This filing is the mechanism for Q2 results dissemination, but the excerpt lacks the quantitative content that typically drives trading decisions.

03

What to watch

Key drivers likely include cash runway, operating expense trajectory, and any updated pipeline or commercialization commentary, none of which are present in the provided text.

Relevance 7/10Novelty 3/10Timing: Filed pre-market/at 09:30:54 ET on Aug 12, 2026 with Q2 results press release furnished as Exhibit 99.1.

Background

The company furnished an 8-K under Item 2.02 to report its financial results for the second quarter ended June 30, 2026, attaching a press release as Exhibit 99.1.

Company-level read

Ticker impact

$MNPRNeutralLow confidence
Context

Monopar filed an 8-K furnishing its Q2 2026 results press release for the quarter ended June 30, 2026.

Expected impact

Near-term volatility possible on release day, but direction cannot be inferred from the provided excerpt.

Evidence & confidence

The filing confirms the company issued Q2 2026 results via Exhibit 99.1, yet the excerpt contains no revenue, EPS, cash, or outlook numbers to assess beat/miss or changes.

Market effects

No sector read-through is provided in the excerpt beyond routine quarterly reporting.

None indicated.

None indicated.

Counterpoint

Without the actual Q2 numbers or guidance in the excerpt, the market reaction may be driven by details not captured here, so traders should verify Exhibit 99.1 before trading.

Key entities

  • Monopar Therapeutics Inc.

    Nasdaq-listed issuer that furnished its Q2 2026 results press release via 8-K Item 2.02.

  • Quan Vu

    Chief Financial Officer who signed the 8-K.

Related articles

$MNPRMed

Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, November 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative t

$MNPRMedAI 8/10

Monopar presents Wilson disease trial data at liver conference

Monopar Therapeutics (MNPR) presented Phase 3 FoCus trial data for Wilson disease at a liver conference. Key findings include high rates of cirrhosis, neurologic, and psychiatric symptoms among patients. ALXN1840, its investigational therapy, showed positive long-term data. The trial is the largest randomized controlled study in Wilson disease.

$MNPRMedAI 8/10

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

Monopar Therapeutics (MNPR) presented data from its Phase 3 FoCus trial at AASLD 2026, showing significant disease burden in Wilson disease patients, including cirrhosis, neurologic, and psychiatric symptoms. ALXN1840, Monopar's investigational therapy, demonstrated long-term safety with neutral molybdenum balance and normal uric acid levels over six years.

$MNPRMedAI 8/10

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Therapeutics presented Phase 2 ALXN1840 (tiomolibdate choline) data at EASL 2026 for treatment-experienced Wilson disease patients. In an open-label, multicenter 48-week trial (29 patients; 24 with paired biopsies), histology showed stabilization or improvement in multiple liver measures, with no statistically significant change in hepatic copper. The company also reported significant improvements in UWDRS Part III, CGI, and EQ-5D UK, with generally nonserious Grade 1–2 adverse events.

$HDMedAI 8/10

Home Depot Just Delivered Great News to Investors

Home Depot (HD) reported its strongest same-store sales growth since Q3 2022, with 2.2% global and U.S. growth. CFO Richard McPhail becomes CEO, while Ted Decker transitions to chairman. Revenue rose 4.9% to $43.4B, and adjusted EPS increased 3% to $3.86. The company updated its full-year guidance, expecting 4.5% sales growth and 2% EPS increase. Management highlighted strength in professional and high-ticket sales.